D. Brusquant

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.

W. Scheithauer, F. Bonnetain, A. de Gramont, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer--A GERCOR Study.

F. Bonnetain, P. Hammel, A. Gramont, 2015 .

Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study

F. Pruvot, M. Hebbar, F. Bonnetain, 2013, Journal of chemotherapy.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Christophe Tournigand, Franck Bonnetain, Olivier Dupuis, 2016, Cancer medicine.

BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC.

M. Ronot, V. Paradis, E. Raymond, 2016 .

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial

M. Hebbar, F. Bonnetain, A. de Gramont, 2016, PloS one.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of age on treatment efficacy and safety in metastatic colorectal cancer: A subgroup analysis from the GERCOR Dream phase III study

C. Tournigand, A. Gramont, B. Chibaudel, 2012 .

Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2013 .